Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon and Flat6Labs Launch Second Edition of Women’s Health Accelerator Program, addressing Women’s Health Challenges Across MENAT

Save Print

April 15, 2024 9:05 am EDT

  • Celebrating International Women’s Day by empowering female-led innovation in healthcare
  • Initiative to power FemTech advancements in family planning, fertility, and women’s wellness
  • [Aligns with UAE’s ‘National Policy for Improving Women’s Health’]

29 February 2024, Dubai, UAE: Organon, a global healthcare company dedicated to improving women’s health, in partnership with Flat6Labs, MENA’s leading seed and early-stage venture capital firm, has announced the launch of the second edition of the Women’s Health Accelerator Program. The initiative aims to empower digital health startups with solutions to enhance women’s health across the Middle East, North Africa, and Turkey (MENAT) region.

The launch follows the overwhelming success of the inaugural Accelerator Program, where three standout female-founded digital health start-ups were honored in MENA as winners, including UAE founded ‘Maternally,’ a platform successfully supporting women’s mental health needs. The accelerator initiative was launched to address specific health challenges faced by women in the region, aiming to find sustainable and long-term solutions.

Aligning with the UAE’s inspiring ‘National Policy for Improving Women’s Health,’ the second edition of the program focusses on innovation across three areas including family planning, fertility, and women’s wellness. The emphasis is on digital solutions that can help improve accessibility, empower individuals, and enhance overall quality of well-being, ultimately advancing women’s healthcare.

Ramy Koussa – Associate Vice President for Middle East, North Africa & Turkey (MENAT) at Organon, said: “Launching the second edition of the Women’s Health Accelerator Program marks a significant milestone in our ongoing commitment to advancing women’s health in the MENAT region. Investing in improving women’s health not only improves women’s quality of life but also enables them to thrive in the workforce. Therefore, we want to support entrepreneurs to drive forward the next wave of innovations and solutions.”

He further commented: “We are excited to deepen our partnership with Flat6Labs and continue listening to the needs of women, identifying innovative solutions that foster a better and healthier every day for her. This edition is a testament to our sustained dedication to collaboration, innovation, and the empowerment of women and startups who have new digital solutions in the women health space.”

Yehia Houry, Chief Programs Officer at Flat6Labs, emphasized the importance of supporting entrepreneurs and advancing women’s healthcare, stating, “As we embark on the second edition of the Women’s Health Accelerator Program, we are thrilled to amplify our support for entrepreneurs shaping the future of women’s healthcare. This initiative is not just about innovation; it’s about empowering visionary minds to create lasting impact. Our ongoing partnership with Organon and the evolving focus of this edition reaffirm our commitment to fostering a dynamic ecosystem for women-led startups. Together, we aim to revolutionize the healthcare landscape, ensuring it reflects the diverse and nuanced needs of women across the MENAT region.”

As well as improving exposure and visibility to key stakeholders in the healthcare sector, the program will include community events, such as specialized training sessions and seminars to enhance the exchange of ideas and experiences in commercial and technical aspects, which will contribute to providing startups with the knowledge and skills necessary to expand the scope of their business.

The three core focus areas include family planning, utilizing technologies to offer advice and raise awareness about various family planning methods available to women. Secondly, fertility planning, honing in on solutions for IVF Mental Health Support and Counseling. Thirdly, innovations that benefit women’s wellness, with a particular focus on self and maternal care, disease prevention and menstrual health.

For more information about the Women’s Health Accelerator Program’s second edition and the application process, please visit the website here. The applications close on May 16, 2024. The countries in the program include UAE, Kuwait, Lebanon, Oman, Turkey, Egypt, Jordan, and Saudi Arabia.

What can we help you find?

Search for:
META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept